Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.

Activating mutations in BRAF and NRAS oncogenes in human melanomas are mutually exclusive. This finding has suggested an epistatic relationship but is consistent even with synthetic lethality. To evaluate the latter possibility, a mutated NRAS(Q61R) oncogene was expressed, under a constitutive or a doxycycline-regulated promoter, in a metastatic melanoma clone (clone 21) harboring an activated BRAF(V600E) oncogene. After the first 10 to 12 in vitro passages, the constitutive NRAS(Q61R) transfectant displayed progressive accumulation in G(0)-G(1) phase of the cell cycle and stained for the senescence-associated beta-galactosidase activity (SA-beta-Gal). Inducible expression of NRAS(Q61R), by the Tet-Off system, in clone 21 cells (21NRAS(61ON)) led to overactivation of the RAS/RAF/mitogen-activated protein kinase signaling pathway and, after the 10th in vitro passage, led to promotion of senescence. This was documented by reduced proliferation, flattened cell morphology, reduced growth in Matrigel, positive staining for SA-beta-Gal, and expression of AMP-activated protein kinase and of the cell cycle inhibitor p21(waf1/Cip1). These effects were detected neither in 21 cells with silenced NRAS(Q61R) (21NRAS(61OFF)) nor in cells transfected with an inducible wild-type NRAS gene (21NRAS(WTON)). In addition, when compared with parental 21 cells, or with 21NRAS(61OFF), 21NRAS(61ON) and constitutive NRAS(Q61R) transfectants cells showed increased susceptibility to cytotoxicity by both HLA class I antigen-restricted and nonspecific T cells and up-regulation of several MHC class I antigen processing machinery components. These results suggest a relationship of synthetic lethality between NRAS and BRAF oncogenes, leading to selection against "double-mutant" cells.

[1]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[2]  J. Whelan,et al.  Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. , 1983, Journal of immunology.

[3]  A. Anichini,et al.  Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction. , 1989, Journal of immunology.

[4]  H. Kleinman,et al.  Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with Matrigel. , 1991, Journal of the National Cancer Institute.

[5]  C Roskelley,et al.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A Sewing,et al.  High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1 , 1997, Molecular and cellular biology.

[7]  J. Bos,et al.  Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras , 1997, Oncogene.

[8]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[9]  A. Albini,et al.  Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. , 1998, Pathology oncology research : POR.

[10]  S. Lowe,et al.  Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. , 1998, Genes & development.

[11]  V. Cerundolo,et al.  An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (Ctl)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific Ctls but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions , 1999, The Journal of experimental medicine.

[12]  A. Anichini,et al.  Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions. , 1999, Journal of immunology.

[13]  K Watanabe,et al.  Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  F. Haluska,et al.  Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. , 2000, Cancer research.

[15]  D. Majumdar,et al.  Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. , 2000, Cancer research.

[16]  F. Zunino,et al.  Membrane gamma-glutamyl transpeptidase activity of melanoma cells: effects on cellular H(2)O(2) production, cell surface protein thiol oxidation and NF-kappa B activation status. , 2000, Journal of cell science.

[17]  V. Cerundolo,et al.  Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. , 2000, Cancer research.

[18]  Liya Liu,et al.  Minimal FLAG sequence useful in the functional epitope tagging of H-Ras. , 2002, BioTechniques.

[19]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[20]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[21]  K. Kinzler,et al.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.

[22]  A. Menssen,et al.  Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. , 2002, The Journal of clinical investigation.

[23]  S. Ferrone,et al.  Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. , 2003, Tissue antigens.

[24]  K. Hemminki,et al.  Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9 , 2003, Oncogene.

[25]  David E Fisher,et al.  Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival , 2003, Oncogene.

[26]  M. Gorospe,et al.  Increased AMP:ATP Ratio and AMP-activated Protein Kinase Activity during Cellular Senescence Linked to Reduced HuR Function* , 2003, Journal of Biological Chemistry.

[27]  I. Shih,et al.  Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.

[28]  C. Springer,et al.  V599EB-RAF is an Oncogene in Melanocytes , 2004, Cancer Research.

[29]  M. Pierotti,et al.  BRAF alterations are associated with complex mutational profiles in malignant melanoma , 2004, Oncogene.

[30]  A. Anichini,et al.  Apoptosis Protease Activator Protein-1 Expression Is Dispensable for Response of Human Melanoma Cells to Distinct Proapoptotic Agents , 2004, Cancer Research.

[31]  Markus Ringnér,et al.  Microarray expression profiling in melanoma reveals a BRAF mutation signature , 2004, Oncogene.

[32]  P. Cresswell,et al.  Recent developments in MHC-class-I-mediated antigen presentation. , 2004, Current opinion in immunology.

[33]  J. Shay,et al.  Hallmarks of senescence in carcinogenesis and cancer therapy , 2004, Oncogene.

[34]  N. Ruderman,et al.  AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. , 2004, Biochemical and biophysical research communications.

[35]  N. Copeland,et al.  Melanocytes and the microphthalmia transcription factor network. , 2004, Annual review of genetics.

[36]  David E. Misek,et al.  Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis , 2005, Oncogene.

[37]  L. Larue,et al.  Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression , 2005, Nature.

[38]  J. Campisi.  Senescent Cells, Tumor Suppression, and Organismal Aging: Good Citizens, Bad Neighbors , 2005, Cell.

[39]  Keith W. Vance,et al.  Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. , 2005, Cancer research.

[40]  R. Marais,et al.  The role of B-RAF in melanoma , 2005, Cancer and Metastasis Reviews.

[41]  K. Hemminki,et al.  BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. , 2005, The Journal of investigative dermatology.

[42]  D. Hardie,et al.  New roles for the LKB1-->AMPK pathway. , 2005, Current opinion in cell biology.

[43]  R. Marais,et al.  Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation , 2005, The Journal of cell biology.

[44]  W. Kaelin.  The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[45]  P. Khavari,et al.  Use of human tissue to assess the oncogenic activity of melanoma-associated mutations , 2005, Nature Genetics.

[46]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[47]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[48]  A. Dolnikov,et al.  N-ras-induced growth suppression of myeloid cells is mediated by IRF-1. , 2005, Cancer research.

[49]  H. Cho,et al.  Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. , 2005, Tissue antigens.

[50]  Ikuo Konishi,et al.  BRAF Mutation in Endometrial Carcinoma and Hyperplasia: Correlation with KRAS and p53 Mutations and Mismatch Repair Protein Expression , 2005, Clinical Cancer Research.

[51]  C. Warneke,et al.  Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. , 2006, The Journal of investigative dermatology.

[52]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.